Show simple item record

dc.contributor.authorCruz‐Ares, Silvia de la
dc.contributor.authorCardelo, Magdalena P.
dc.contributor.authorGutiérrez Mariscal, Francisco Miguel
dc.contributor.authorTorres‑Peña, J.D.
dc.contributor.authorGarcía-Ríos, Antonio
dc.contributor.authorKatsiki, Niki
dc.contributor.authorMalagón, María M.
dc.contributor.authorLópez-Miranda, José
dc.contributor.authorPérez-Martínez, Pablo
dc.contributor.authorYubero-Serrano, Elena M.
dc.date.accessioned2020-01-21T13:18:48Z
dc.date.available2020-01-21T13:18:48Z
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/10396/19343
dc.description.abstractEndothelial dysfunction and intima-media thickness of common carotid arteries (IMT-CC) are considered subclinical markers of atherosclerotic cardiovascular disease (ASCVD). Advanced glycation end products (AGEs) are increased in type 2 diabetes mellitus (T2DM) patients, compared with non-diabetics, being implicated in micro- and macrovascular complications. Our aim was to compare serum AGEs levels and subclinical atherosclerotic markers between patients with established and newly diagnosed T2DM. Among 540 patients with T2DM and coronary heart disease from the CORDIOPREV study, 350 patients had established T2DM and 190 patients had newly diagnosed T2DM. Serum levels of AGEs (methylglyoxal (MG) and N-carboxymethyl lysine (CML)) and subclinical atherosclerotic markers (brachial flow-mediated vasodilation (FMD) and IMT-CC) were measured. AGEs levels (all p < 0.001) and IMT-CC (p = 0.025) were higher in patients with established vs. newly diagnosed T2DM, whereas FMD did not differ between the two groups. Patients with established T2DM and severe endothelial dysfunction (i.e., FMD < 2%) had higher serum MG levels, IMT-CC, HOMA-IR and fasting insulin levels than those with newly diagnosed T2DM and non-severe endothelial dysfunction (i.e., FMD ≥ 2%) (all p < 0.05). Serum CML levels were greater in patients with established vs. newly diagnosed T2DM, regardless of endothelial dysfunction severity. Serum AGEs levels and IMT-CC were significantly higher in patients with established vs. newly diagnosed T2DM, highlighting the progressively increased risk of ASCVD in the course of T2DM. Establishing therapeutic strategies to reduce AGEs production and delay the onset of cardiovascular complications in newly diagnosed T2DM patients or minimize ASCVD risk in established T2DM patients is needed.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightshttps://creativecommons.org/licenses/by/4.0/es_ES
dc.sourceNutrients 12(1), 238 (2020)es_ES
dc.subjectCORDIOPREVes_ES
dc.subjectType 2 diabetes mellituses_ES
dc.subjectEndothelial dysfunctiones_ES
dc.subjectAdvanced glycation end productses_ES
dc.subjectMethylglyoxales_ES
dc.subjectN‐carboxymethyl lysinees_ES
dc.subjectFlow‐mediated vasodilationes_ES
dc.subjectIntima‐media thickness of common carotid arterieses_ES
dc.titleEndothelial Dysfunction and Advanced Glycation End Products in Patients with Newly Diagnosed Versus Established Diabetes: From the CORDIOPREV Studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.3390/nu12010238es_ES
dc.relation.projectIDJunta de Andalucía. PI‐0283/2017es_ES
dc.relation.projectIDInstituto de Salud Carlos III. FIS PI18/01822es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record